-
Chapter
Therapeutic Potential of Tachykinin Receptor Antagonists in Depression and Anxiety Disorders
Neuropeptides, including the tachykinins substance P, neurokinin A and neurokinin B, are potentially important new targets for the development of psychotropic drugs. NK1, NK2 and NK3 tachykinin receptor antagonis...
-
Chapter
Neurotrophic Factors in Peripheral Nerve Injury and Regeneration
Damage to the human peripheral nervous system can result from many types of insult; examples are diabetes, traumatic injury, cytotoxic drugs, radio-therapy, infection, environmental pollutants such as organoph...
-
Article
Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys
Hepatotoxicity limits the clinical utility of the cholinesterase inhibitor tacrine as a palliative therapy for Alzheimer’s disease. The present studies examined the effects of E2020, a selective acetylcholine...
-
Chapter
L-DOPA-Induced Chorea and Dystonia in MPTP-Treated Squirrel Monkeys
Administration of L-DOPA to Parkinsonian patients frequently induces a range of disabling involuntary movements of which chorea and dystonia are the most common. Choreiform movements are often associated with ...
-
Chapter
Heptylphysostigmine — Novel Acetylcholinesterase Inhibitor: Biochemical and Behavioral Pharmacology
The discovery in the 1970’s that choline acetyltransferase (ChAT) is markedly reduced in the brains of patients with Alzheimer’s disease (AD) compared with those of age-matched controls (Bowen et al., 1976) pr...
-
Article
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Drug-induced purposeless chewing movements in rodents are often considered to represent movement disorders or dyskinesias. We have compared the ability of drugs to induce chewing and retching or emesis in squi...
-
Article
Characterisation of dyskinesias induced byl-dopa in MPTP-treated squirrel monkeys
Intermittent treatment withl-dopa over a 2-year period induced abnormal involuntary movements in MPTP-treated squirrel monkeys. Dyskinesias included a choreic and dystonic component. Dose-response curves for chor...
-
Article
Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects
The ability of four central cholinomimetics to reverse a scopolamine-induced spatial memory impairment or to improve visual recognition memory in primates was examined. Physostigmine (0.04–0.08 mg/kg IM) fully...
-
Article
Alterations in cerebral glutamic acid decarboxylase and3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine
Rats were treated continuously for 12 months with therapeutically equivalent doses of haloperidol (1.4–1.6 mg/kg/day), sulpiride (102–109 mg/kg/day) or clozapine (24–27 mg/kg/day) and examined for alterations ...
-
Article
Acute dystonia induced by neuroleptic drugs
About 2.5% of patients treated with neuroleptic drugs develop acute dystonia within 48 h of commencing therapy. The symptoms remit on drug withdrawal or following anticholinergic therapy. Acute dystonia can al...
-
Chapter and Conference Paper
Differential Alteration of Striatal D-1 and D-2 Receptors Induced by the Long-Term Administration of Haloperidol, Sulpiride or Clozapine to Rats
Rats received haloperidol, sulpiride, or clozapine in their daily drinking water for up to 1 year in clinically equivalent doses. After 12 months’ drug intake, and while drug administration continued, striatal...
-
Article
Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats
Continuous administration of haloperidol, sulpiride, or cis-flupenthixol, but not of domperidone or apomorphine, to Wistar rats for up to 3 weeks caused an increase in spontaneous purposeless chewing movements. T...
-
Article
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat
Administration of haloperidol (1.4–1.6 mg/kg/day) for up to 12 months or sulpiride (102–109 mg/kg/day) for between 6 and 12 months increased the frequency of purposeless chewing jaw movements in rats. N,n-propyln...
-
Article
Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats
Rats received therapeutically equivalent doses of either haloperidol (1.7–1.9 mg/kg/day), sulpiride (112–116 mg/kg/day) or clozapine (30–35 mg/kg/day) continuously for 4 weeks. Treatment with haloperidol, but ...
-
Article
Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats
Rats treated continuously for 4 months with haloperidol (1.4–1.6 mg/kg/day), trifluoperazine (4.5–5.1 mg/kg/day), or sulpiride (102–110 mg/kg/day), but not clozapine (23–26 mg/kg/day), exhibited an increased f...
-
Chapter and Conference Paper
Long-Term Adaptive Changes in Striatal Dopamine Function in Response to Chronic Neuroleptic Intake in Rats
Chronic neuroleptic drug administration to rats reverses initial dopamine receptor blockade so that animals exhibit striatal dopamine receptor supersensitivity. This effect may be of functional significance in...
